The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations During the Covid-19 Pandemic Publisher Pubmed



Azimzadeh M¹ ; Mohn N² ; Ghane Ezabadi S³ ; Moghimi Esfandabadi Z⁴ ; Soleimani A⁵ ; Ranjbar E⁶ ; Jahromi M⁷ ; Seyedebrahimi R⁸ ; Skripuletz T² ; Moharrami Kasmaie F⁹
Source: Biomolecules Published:2021

Abstract

A growing body of evidence initially suggested that patients with multiple sclerosis (MS) might be more susceptible to coronavirus disease 2019 (COVID-19). Moreover, it was speculated that patients with MS treated with immunosuppressive drugs might be at risk to develop a severe diseases course after infection with the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV2). However, the recently published data have shown that MS patients do not have a higher risk for severe COVID-19. Although there is no indication that patients with MS and immunomodulatory/immunosuppressive therapy are generally at a higher risk of severe COVID-19, it is currently being emphasized that the hazards of poorly treated MS may outweigh the putative COVID-19 dangers. In this review, we discuss the challenges and considerations for MS patients in the COVID-19 pandemic. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.